Godecke Aktiengesellschaft

Goedecke Aktiengesellschaft

Warner-lambert Company

Gunter Weinheimer

Johannes Hartenstein

Hartmut Osswald

Jurgen Kleinschroth

Claus Rudolph

Karl Mannhardt

Gerhard Satzinger

Edgar Fritschi

Christoph Schachtele

Julian Aranda

Reinhard Reck

Hubert G Barth

Bernd Wagner

Uwe Trostmann

Christopher Schachtele

New indolocarbazoles of formula: ##STR1## or a pharmaceutically acceptable salt thereof, processes for their preparation, compositions containing, and methods for using the composition for the inhibition of protein kinases, such as protein kinase C, for the prevention and/or treatment of heart and blood vessel diseases such as thromboses, arterioscleroses, hypertension, or for inflammatory processes, allergies, cancers, viral diseases, and certain degenerative damages of the central nervous system are disclosed.

Indolocarbazole derivatives, processes for their preparation and

2-aminocarboxylic acids and their derivatives, processes for their

The invention concerns new derivatives of certain alkoxy-4(1H)-pyridones, processes for preparing them, and pharmaceutical compositions containing them. The compounds of the invention are useful in the prevention and/or treatment of heart and blood vessel diseases such as thromboses, arteriosclerosis and hypertension, and of inflammatory processes, allergies, cancers, and certain degenerative damage of the central nervous system.

Alkoxy-4 (1H)-pyridone derivatives, processes for the preparation

Alkoxy-4(1H)-pyridone derivatives, processes for the preparation thereof

4-Alkoxy-pyrido[2,3-d]pyrimidine derivatives are described as well as processes for their preparation. For reason of their vasospasmolytic effects these compounds are mainly indicated for the treatment of cerebral, cardiac, and peripheral vascular diseases such as myocardiac ischemia, cerebral infarction, pulmonary thromboses, as well as in cases of arterioschlerosis and other stenotic disorders. They are therefore valuable agents for combating cardiovascular mortality.

4-alkoxy-pyrido[2,3-d]pyrimidine derivatives for treatment of myocardiac

The present invention describes 1,6-naphthyridine derivatives of the general formula: ##STR1## wherein R.sup.1 is an unsubstituted or substituted aromatic or heteroaromatic ring, R.sup.2 is a straight-chained or branched alkyl radical containing up to four carbon atoms or a benzyl radical, R.sup.3 is a hydrogen atom, a straight-chained or branched alkyl radicals or an alkoxycarbonyl radical containing up to four carbon atoms, R.sup.4 is a straight-chained or branched alkyl radical containing up to four carbons and R.sup.5 is a carboxyl group or a straight-chained, branched or cyclic alkoxycarbonyl radical which contains up to 17 carbon atoms and optionally also contains an oxygen, sulphur or nitrogen atom; as well as the pharmacologically acceptable salts thereof, which are useful for treating diseases of the blood vessels.

1,6-naphthyridine derivatives useful for treating diseases of the blood

The present invention provides a unique series of pyrido[4,3-b][1,6]naphthyridine derivatives. The compounds are calcium antagonists and are useful for blood vessel diseases. This invention also covers processes for preparing the compounds, pharmaceutical compositions containing them, and methods for using them.

Treating blood vessel diseases with

4-Oxo-pyrido[2,3-d]pyrimidine derivatives are herein described as well as processes for their preparation. These compounds possess valuable pharmacological properties. As calcium antagonists they exert vasospasmolytic, vasodilatory, and antihypertensive activities. Surprisingly some of the compounds also have the effect of increasing contractility. They are therefore particularly suited for the treatment of vascular diseases.

4-oxo-pyrido[2,3-d]pyrimidinone derivatives

Growing community of inventors

Denzlingen, Germany

Gunter Weinheimer